XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2018
Income Taxes |
Income Taxes | 9. Income Taxes The components of the gross deferred tax asset and related valuation allowance at December 31 were as follows:
|  | 2018 |  | 2017 |
Deferred tax assets: |  |  |  |  |  |  |
Net operating loss carryforward |  | $ | 41,687,577 |  | $ | 30,813,509 |
Capitalized start-up costs |  |  | 1,501,895 |  |  | 1,695,688 |
Patent amortization |  |  | 119,888 |  |  | 135,358 |
Research and orphan drug credits |  |  | 28,123,082 |  |  | 21,293,509 |
Deferred rent |  |  | 51,400 |  |  | 71,938 |
Deferred compensation |  |  | 3,293,221 |  |  | 2,274,885 |
Other |  |  | 95,564 |  |  | 69,906 |
Total gross deferred tax assets |  |  | 74,872,627 |  |  | 56,354,793 |
Valuation allowance |  |  | (74,872,627) |  |  | (56,354,793) |
Deferred tax assets |  |  | — |  |  | — |
Deferred tax liabilities: |  |  |  |  |  |  |
Total deferred tax liabilities |  |  | — |  |  | — |
Net deferred tax assets |  | $ | — |  | $ | — |
Based on the Company’s operating history and management’s expectation regarding future profitability, management believes the realization of the Company’s deferred tax assets does not meet the more-likely-than-not criteria under ASC 740, Income Taxes. Accordingly, a full valuation allowance has been established as of December 31, 2018 and 2017. On December 22, 2017, the Tax Cuts and Jobs Act (the “TCJA”) was enacted into law. The TCJA contained several key tax provisions including the reduction of the corporate income tax rate from 35% to 21% effective January 1, 2018, as well as a variety of other changes, including the limitation of the tax deductibility of interest expense, acceleration of expensing of certain business assets and reductions in the amount of executive pay that can qualify as a tax deduction. ASC Topic 740 required the Company to recognize the effect of the tax law changes in the period of enactment. The Company re-measured certain of its U.S. deferred tax assets and liabilities, based on the rates at which they are expected to reverse in the future. As of December 31, 2017, the tax benefit recorded related to the re-measurement of the deferred tax balance was $15.2 million, which was offset by the related valuation allowance. The Company did not adjust the provisional amount estimated at December 31, 2017 upon its final analysis during the year ended December 31, 2018 of the income tax effects due to the enactment of the TCJA. As of December 31, 2018, the Company had $151.5 million of U.S. Federal and state net operating losses, $8.5 million of research and development tax credits and $19.6 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. The Company’s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company’s ability to utilize its net operating losses and credits. As of December 31, 2018, the Company does not believe that an ownership change has occurred. Any future ownership changes may cause a limitation on the Company’s ability to utilize existing tax attributes. The Company files income tax returns in the U.S. federal jurisdiction and in the State of Maryland. The Company’s federal income tax returns for tax years 2003 and after remain subject to examination by the U.S. Internal Revenue Service. The Company’s Maryland income tax returns for the tax years 2006 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment. The Company did not have unrecognized tax benefits as of December 31, 2018 and 2017, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December 31:
|  | 2018 |  | 2017 |  | 2016 |
U.S. Federal statutory tax rate |  | 21.0 | % | 34.0 | % | 34.0 | %
State taxes |  | 5.7 |  | 4.4 |  | 4.6 |
Research credit |  | 0.8 |  | 1.3 |  | 1.0 |
Orphan drug credit |  | 10.4 |  | 11.5 |  | 9.0 |
Other |  | 0.6 |  | 0.3 |  | — |
Stock-based compensation |  | (0.1) |  | (0.7) |  | (0.7) |
Change in valuation allowance |  | (38.4) |  | (5.1) |  | (47.9) |
Effective change due to corporate tax rate reduction |  | — |  | (45.7) |  | — |
Provision for income taxes |  | — | % | — | % | — | %

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -URI http://asc.fasb.org/topic&trid=2144680 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration